Nationwide Shortage of Albuterol Inhalers and Off-Label Use in COVID-19 Patients
| Autor: | Leslie Hendeles, Sreekala Prabhakaran |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pulmonary and Respiratory Medicine
2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Economic shortage Off-label use respiratory tract diseases Pharmacology Update Pediatrics Perinatology and Child Health Emergency medicine medicine Immunology and Allergy business |
| Zdroj: | Pediatr Allergy Immunol Pulmonol |
| ISSN: | 2151-3228 |
| Popis: | The surge in COVID-19 cases during the 2020 Spring led to a nationwide shortage of albuterol inhalers. As a new surge has begun, shortages may make it difficult for patients with obstructive lung disease, including children with asthma, to obtain refills. Since there is no evidence that albuterol relieves symptoms in COVID-19 patients with respiratory symptoms not caused by bronchospasm, it is reasonable for clinicians to not prescribe it for COVID-19 patients unless they also have asthma or chronic obstructive pulmonary disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|